Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Medtronic completes acquisition of Affera PR Newswire Aug 30, 2022, 05:05 AM MDT Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias DUBLIN, Aug. 30, 2022 /PRNewswire/ Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. Actual results may differ materially from anticipated results. "The Affera team is very excited to be joining Medtronic Cardiac Ablation Solutions. Aug 30, 2022 Medtronic completes acquisition of Affera Cardiovascular Portfolio Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias These forward-looking statements speak only as of the date of this document, and Medtronic undertakes no obligation to update or revise any of these statements except to the extent required by law. The consolidated technologies by both companies will deliver advanced solutions to address the rapidly . Jan 24, 2020. WATERTOWN, MA - Affera, Inc., a private medical device company focused on innovative cardiac arrhythmia treatment solutions, announced today first-in-human use of its circumferential Pulmonary Vein Isolation (PVI) Pulsed Field Ablation (PFA) catheter, SpherePVI. Medtronic has completed the acquisition of Affera. Financial HighlightsConsistent with the financial impact disclosed in January 2022 when the Affera transaction was announced, Medtronic expects the transaction to be less than 1% dilutive to Medtronic's adjusted earnings per share in each of the first three years, and neutral to accretive thereafter. DUBLIN, Jan. 10, 2022 / PRNewswire (opens new window) / -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. This milestone is a result of incredible efforts and talent of an entire ecosystem including the Affera, Inc.team, clinical collaborators, investors and countless other professionals. Doron serves as a Board Member at Lexington Medical. Medtronic completes acquisition of Affera. Actual results may differ materially from anticipated results. Acquiring Organization: Medtronic Medtronic develops and manufactures medical device technologies and therapies to treat chronic diseases worldwide. Ireland-based Medtronic surged into 2022 with the acquisition of privately-held Affera, Inc., a company that designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies.. AF represents the largest disease segment, with nearly 60 million people affected worldwide1. Announced Date Jan 10, 2022 Affera is a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing demands for cardiac arrhythmia treatment. August 30, 2022 - 8:00 am. Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias. 77% of retail CFD accounts lose money, https://www.prnewswire.com/news-releases/medtronic-completes-acquisition-of-affera-301614195.html, Pre-market Movers: NRBO, HIMS, OCUP, TRIP, TTWO, Medtronic says trial for renal denervation system did not meet main goal in hypertension, Needham Keeps Their Hold Rating on Medtronic (MDT), Medtronic (MDT) Receives a Hold from BTIG, Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know, SPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials, Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It, Medtronic (MDT) Gains As Market Dips: What You Should Know, Registration on or use of this site constitutes acceptance of our. August 30 2022 - 08:00AM. All rights reserved. For more information, visit www.affera.com. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution. www.affera.com Ownership Status Privately Held (backing) Financing Status Formerly VC-backed Primary Industry Therapeutic Devices Primary Office 320 Nevada Street Suite 401 Newton, MA 02460 United States +1 (857) 000-0000 Affera Timeline 2019 2020 2021 2022 Financing Round Captured Employee Count Estimated Employee Growth Affera is a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing demands for cardiac arrhythmia treatment. Affera is a medical technology company dedicated to delivering unrivaled innovative solutions to address the rapidly growing demands for cardiac arrhythmia treatment. By continuing to use our service, you agree to our use of cookies. Affera's product portfolio is not currently approved or available for sale or commercial use. View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-completes-acquisition-of-affera-301614195.html, Plus500. Medtronic to acquire Affera, a cardiac arrhythmia technology firm, for $925 million Affera makes cardiac mapping and navigation systems and catheter-based cardiac ablation technologies. DUBLIN, Aug. 30, 2022 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. Additional Affera pipeline products such as the Arc-10 coronary sinus (CS) diagnostic catheter and Sphere PVI ablation catheter, which is a single shot device which delivers pulsed field ablation (PFA) energy, are also included. "This acquisition marks an important growth milestone for our cardiac ablation portfolio," said Rebecca Seidel, president of the Cardiac Ablation Solutions (CAS) business, which is part of the Cardiovascular Portfolio at Medtronic. This is a meaningful growth milestone for our Cardiac Ablation Liked by Victoria Low Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Slectionnez Grer les paramtres pour grer vos prfrences. "Our team designed the Affera platform with physicians and patients in mind, to advance the field of electrophysiology while supporting safe and efficient cardiac ablation procedures.". By Burl. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. Medtronic recently announced that its acquisition of Affera, Inc. has been completed. Bolder actions. 1 Roth GA, Mensah GA, Johnson CO et al. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Returning guest, Rebecca Seidel, President, Cardiac Ablation Solutions Operating Unit at Medtronic discusses the recent acquisition of Affera, Inc, a medical. AF represents the largest disease segment, with nearly 60 million people affected worldwide1. DUBLIN, Aug. 30, 2022 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. The Affera full suite of solutions and technologies will complement the existing Medtronic atrial and ventricular arrhythmia disease management portfolio and support the company's efforts to offer differentiated, safe, and effective cardiac ablation solutions. Affera is developing a. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. Medtronic completes acquisition of Affera Aug 30, 2022 (PRNewswire via COMTEX) -- PR Newswire DUBLIN, Aug. 30, 2022 Acquisition adds mapping and navigation platform to company's cardiac. The acquisition enhances and accelerates our ability to treat millions of patients around the world suffering from cardiac arrhythmia with our innovative technology," said Doron Harlev, founder and chief executive officer of Affera. We are Medtronic. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution. Given the timing of today's closing announcement, this translates into approximately 3 to 4 cents in fiscal year 2023, approximately 5 cents in fiscal year 2024, and approximately 4 cents in fiscal year 2025. Stockhouse.com uses cookies on this site. Published: Jan 10, 2022. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. Medtronic plc, a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. The company continues to expect dilution of approximately 5 cents in both year 1 and year 2 and approximately 3 cents in year 3. About MedtronicBold thinking. Jan 10, 2022 07:25AM EST. Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. This acquisition expands the company's cardiac ablation portfolio to include its first-ever cardiac mapping and navigation platform that encompasses a differentiated, fully integrated diagnostic, focal pulsed field and radiofrequency ablation solution. Nous, Yahoo, faisons partie de la famille de marques Yahoo. (RTTNews) - Healthcare technology firm Medtronic plc (MDT) announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area . Prior to striking the deal, Medtronic held a 3% stake in the Boston-based company. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Consistent with the financial impact disclosed in January 2022 when the Affera transaction was announced, Medtronic expects the transaction to be less than 1% dilutive to Medtronic's adjusted earnings per share in each of the first three years, and neutral to accretive thereafter. J Am Coll Cardiol 2020;76:2982-3021. Affera is developing a. Affera is developing a comprehensive integrated platform to efficiently deliver durable therapy for a broad set of cardiac arrhythmia patients. DUBLIN, Aug. 30, 2022 /PRNewswire/ Medtronic plc (NYSE:MDT), a world chief in healthcare expertise, at the moment introduced that it has accomplished the acquisition of Affera, Inc. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. Bold thinking. Our Work Publications Featured AF Symposium 2021 Live Case 5 min read Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an. Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias.